Allergan has exercised a third option to develop and commercialize DARPin product candidates from Molecular Partners and will receive an exclusive license for select multi-DARPin candidates in ophthalmology, according to a Molecular Partners press release.
DARPin products, a class of protein therapeutics, include the long-acting mono-DARPin abicipar, a drug candidate that inhibits VEGF-A and is currently under investigation for the treatment of wet age-related macular degeneration and diabetic macular edema.
For the exercise of the third option, Allergan will pay regulatory and sales milestone
Uncategorized